$MYGN
MYRIAD GENETICS INC Stock $mygn

$mygn Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000119312516576683 Filed on May 04, 2016

Income Statement

Concept	2016 Q2	2016 Q1	2015 Q1
Revenue	$186.4M	$190.5M	$180.0M
YoY Change	-1.84%	5.83%	-1.6%
Cost Of Revenue	$40.00M	$33.60M	$33.00M
YoY Change	4.17%	1.82%	39.55%
Gross Profit	$146.4M	$156.9M	$147.0M
YoY Change	-3.37%	6.73%	-7.71%
Gross Profit Margin	78.54%	82.36%	81.67%
Selling, General & Admin	$91.30M	$90.50M	$91.30M
YoY Change	-5.49%	-0.88%	4.19%
% of Gross Profit	62.36%	57.68%	62.11%
Research & Development	$19.50M	$17.20M	$16.70M
YoY Change	4.28%	2.99%	24.65%
% of Gross Profit	13.32%	10.96%	11.36%
Depreciation & Amortization	$6.700M	$3.500M	$3.300M
YoY Change	1.52%	6.06%	-5.71%
% of Gross Profit	4.58%	2.23%	2.24%
Operating Expenses	$110.8M	$107.7M	$108.0M
YoY Change	-3.9%	-0.28%	6.9%
Operating Profit	$35.60M	$42.60M	$35.70M
YoY Change	-1.66%	19.33%	-35.43%
Interest Expense	$400.0K	$300.0K	$100.0K
YoY Change	300.0%	200.0%	-96.0%
% of Operating Profit	1.12%	0.7%	0.28%
Other Income/Expense, Net	$1.200M	$500.0K	-$200.0K
YoY Change	-250.0%	-350.0%	-109.73%
Pretax Income	$37.20M	$43.10M	$35.50M
YoY Change	4.79%	21.41%	-38.09%
Income Tax	$1.500M	$10.50M	$14.10M
% Of Pretax Income	4.03%	24.36%	39.72%
Net Earnings	$35.70M	$32.60M	$21.40M
YoY Change	90.91%	52.34%	-41.8%
Net Earnings / Revenue	19.15%	17.11%	11.89%
Basic Earnings Per Share		$0.46	$0.30
Diluted Earnings Per Share	$482.4K	$0.44	$0.29
COMMON SHARES
Basic Shares Outstanding	70.30M shares	70.90M shares	70.70M shares
Diluted Shares Outstanding		73.50M shares	73.90M shares

Balance Sheet

Concept	2016 Q2	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$159.0M	$216.7M	$134.4M
YoY Change	9.81%	61.24%	-36.66%
Cash & Equivalents	$68.50M	$120.5M	$55.20M
Short-Term Investments	$90.50M	$96.20M	$79.20M
Other Short-Term Assets	$22.20M	$36.40M	$23.50M
YoY Change	-14.62%	54.89%	10.85%
Inventory	$38.30M	$25.30M	$29.36M
Prepaid Expenses
Receivables	$91.70M	$91.10M	$92.20M
Other Receivables	$3.300M	$2.900M	$2.992M
Total Short-Term Assets	$314.5M	$372.4M	$282.4M
YoY Change	10.9%	31.86%	-16.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$58.30M	$60.00M	$69.10M
YoY Change	-13.24%	-13.17%	111.54%
Goodwill	$195.3M	$177.9M	$185.2M
YoY Change	10.21%	-3.96%	11.08%
Intangibles	$227.5M	$183.2M	$195.7M
YoY Change	18.12%	-6.38%	-6.05%
Long-Term Investments	$79.90M	$69.70M	$41.20M
YoY Change	96.8%	69.17%	-37.2%
Other Assets	$5.000M	$5.000M	$5.000M
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$566.0M	$495.8M	$496.6M
YoY Change	17.28%	-0.17%	3.84%
TOTAL ASSETS
Total Short-Term Assets	$314.5M	$372.4M	$282.4M
Total Long-Term Assets	$566.0M	$495.8M	$496.6M
Total Assets	$880.5M	$868.2M	$779.0M
YoY Change	14.92%	11.44%	-4.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.10M	$13.80M	$17.96M
YoY Change	0.0%	-23.14%	-5.18%
Accrued Expenses	$49.50M	$50.80M	$47.88M
YoY Change	7.38%	6.1%	-6.31%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$72.30M	$66.10M	$67.17M
YoY Change	5.24%	-1.6%	-6.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.800M	$2.000M	$6.420M
YoY Change	100.0%	-68.85%	-52.79%
Total Long-Term Liabilities	$7.800M	$2.000M	$6.420M
YoY Change	100.0%	-68.85%	-52.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$72.30M	$66.10M	$67.17M
Total Long-Term Liabilities	$7.800M	$2.000M	$6.420M
Total Liabilities	$132.4M	$98.00M	$110.2M
YoY Change	27.19%	-11.03%	16.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$73.20M	-$69.20M	-$62.28M
YoY Change	-4.94%	11.11%	-430.15%
Common Stock	$830.8M	$847.7M	$700.0K
YoY Change	11.35%	121000.0%	-6.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$739.6M	$770.2M	$668.9M
YoY Change
Total Liabilities & Shareholders Equity	$880.5M	$868.2M	$779.0M
YoY Change	14.92%	11.44%	-4.58%

Cashflow Statement

Concept	2016 Q2	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	$35.70M	$32.60M	$21.40M
YoY Change	90.91%	52.34%	-41.8%
Depreciation, Depletion And Amortization	$6.700M	$3.500M	$3.300M
YoY Change	1.52%	6.06%	-5.71%
Cash From Operating Activities	$38.50M	$45.90M	$29.90M
YoY Change	-24.51%	53.51%	164.6%
INVESTING ACTIVITIES
Capital Expenditures	-$2.200M	-$700.0K	-$4.500M
YoY Change	10.0%	-84.44%	181.25%
Acquisitions
YoY Change
Other Investing Activities	-$41.60M	-$15.40M	$29.30M
YoY Change	5100.0%	-152.56%	29200.0%
Cash From Investing Activities	-$43.80M	-$16.10M	$24.90M
YoY Change	1464.29%	-164.66%	-1760.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-46.30M	-44.00M	-56.00M
YoY Change	15.17%	-21.43%	-1700.0%
NET CHANGE
Cash From Operating Activities	38.50M	45.90M	29.90M
Cash From Investing Activities	-43.80M	-16.10M	24.90M
Cash From Financing Activities	-46.30M	-44.00M	-56.00M
Net Change In Cash	-51.60M	-14.20M	-1.200M
YoY Change	-745.0%	1083.33%	-109.02%
FREE CASH FLOW
Cash From Operating Activities	$38.50M	$45.90M	$29.90M
Capital Expenditures	-$2.200M	-$700.0K	-$4.500M
Free Cash Flow	$40.70M	$46.60M	$34.40M
YoY Change	-23.21%	35.47%	166.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70298970	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73500000	shares
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	33800000
CY2015Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	19000000
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73500000	shares
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64800000
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12500000	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68900000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.49
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68900000	shares
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	68700000
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	70900000
CY2015Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	200000
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	46100000
CY2015Q2	us-gaap	Liabilities Liabilities	104100000
CY2015Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	3800000
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	700000
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	745400000
CY2015Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	7600000
CY2015Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	26400000
CY2015Q2	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	4900000
CY2015Q2	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	8800000
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3900000
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1500000
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7000000
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q2	us-gaap	Available For Sale Equity Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	100000
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8500000
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-77000000
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	662100000
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	766200000
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	21100000
CY2015Q2	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	18200000
CY2015Q2	us-gaap	Available For Sale Equity Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	100000
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	192600000
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	67200000
CY2015Q2	us-gaap	Assets Current AssetsCurrent	283600000
CY2015Q2	us-gaap	Land Land	2300000
CY2015Q2	us-gaap	Goodwill Goodwill	177200000
CY2015Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	80700000
CY2015Q2	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	13500000
CY2015Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1900000
CY2015Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	206800000
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	187800000
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	138100000
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5000000
CY2015Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	18500000
CY2015Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	4800000
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64100000
CY2015Q2	us-gaap	Assets Assets	766200000
CY2015Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	130700000
CY2015Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	211600000
CY2015Q2	us-gaap	Investments And Cash InvestmentsAndCash	185400000
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	85800000
CY2015Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	40600000
CY2015Q2	us-gaap	Inventory Net InventoryNet	25100000
CY2015Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	99100000
CY2015Q2	mygn	Prepaid Expense Excluding Prepaid Taxes Current PrepaidExpenseExcludingPrepaidTaxesCurrent	12500000
CY2015Q2	mygn	Investments And Cash At Fair Value InvestmentsAndCashAtFairValue	185400000
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70000000	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70000000	shares
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55200000
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8400000	shares
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	24.02
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70400000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6900000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	24.51
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70400000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	66100000
CY2016Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	47000000
CY2016Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	39700000
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	81700000
CY2016Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	200000
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	50800000
CY2016Q1	us-gaap	Liabilities Liabilities	98000000
CY2016Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	2300000
CY2016Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	28400000
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	700000
CY2016Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	847000000
CY2016Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6500000
CY2016Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	24000000
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q1	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	5700000
CY2016Q1	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	7700000
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2000000
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1500000
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8300000
CY2016Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	0
CY2016Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	96200000
CY2016Q1	us-gaap	Available For Sale Equity Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	400000
CY2016Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8800000
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-69200000
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	770200000
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	868200000
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	13800000
CY2016Q1	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	18800000
CY2016Q1	us-gaap	Available For Sale Equity Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	100000
CY2016Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	183200000
CY2016Q1	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	100000
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	60000000
CY2016Q1	us-gaap	Assets Current AssetsCurrent	372400000
CY2016Q1	us-gaap	Land Land	2300000
CY2016Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	69400000
CY2016Q1	us-gaap	Goodwill Goodwill	177900000
CY2016Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	96200000
CY2016Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2900000
CY2016Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	96200000
CY2016Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	206800000
CY2016Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	178400000
CY2016Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	18700000
CY2016Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	4800000
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	120500000
CY2016Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8600000
CY2016Q1	us-gaap	Assets Assets	868200000
CY2016Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	172200000
CY2016Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	0
CY2016Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	69700000
CY2016Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	211600000
CY2016Q1	us-gaap	Investments And Cash InvestmentsAndCash	286100000
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	91100000
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	141700000
CY2016Q1	us-gaap	Prepaid Taxes PrepaidTaxes	15300000
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5000000
CY2016Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	69700000
CY2016Q1	us-gaap	Inventory Net InventoryNet	25300000
CY2016Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	101900000
CY2016Q1	mygn	Number Of Defined Benefit Pension Plans NumberOfDefinedBenefitPensionPlans	2	plan
CY2016Q1	mygn	Prepaid Expense Excluding Prepaid Taxes Current PrepaidExpenseExcludingPrepaidTaxesCurrent	21100000
CY2016Q1	mygn	Investments And Cash At Fair Value InvestmentsAndCashAtFairValue	286400000
CY2015Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	13500000
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3100000	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	1200000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72000000	shares
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.38	pure
	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	4700000	shares
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	89500000
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.85
	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	1900000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75100000	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.82
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	3200000
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-900000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	55500000
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	516600000
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	20100000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1100000
	us-gaap	Operating Income Loss OperatingIncomeLoss	98000000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4900000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	99400000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-100000
	us-gaap	Revenues Revenues	533200000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	32200000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	300000
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1000000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1400000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	21900000
	us-gaap	Net Income Loss NetIncomeLoss	61500000
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	16600000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-300000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	55100000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5700000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	165900000
	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	-13600000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	22700000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	3000000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18400000
	us-gaap	Depreciation Depreciation	8800000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-137100000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9600000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-5700000
	us-gaap	Cost Of Revenue CostOfRevenue	100900000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	37900000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	25600000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	23500000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	200000
	us-gaap	Costs And Expenses CostsAndExpenses	435200000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9600000
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	3800000
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	-300000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6400000
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	3200000
	us-gaap	Share Based Compensation ShareBasedCompensation	31600000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	269400000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-11500000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	140800000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	43700000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56800000
	mygn	Amount Charged To Retained Earnings As Result Of Stock Repurchases AmountChargedToRetainedEarningsAsResultOfStockRepurchases	125800000
	mygn	Amount Of Reduction In Common Stock As Result Of Stock Repurchases AmountOfReductionInCommonStockAsResultOfStockRepurchases	40200000
	mygn	Cost Of Pharmaceutical And Clinical Services CostOfPharmaceuticalAndClinicalServices	8100000
	dei	Document Type DocumentType	10-Q
	dei	Trading Symbol TradingSymbol	MYGN
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
	dei	Entity Central Index Key EntityCentralIndexKey	0000899923
	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3100000	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	4400000	shares
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70100000	shares
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.32	pure
	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	2900000	shares
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	109900000
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	21.39
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4100000	shares
	dei	Entity Registrant Name EntityRegistrantName	MYRIAD GENETICS INC
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	Segment
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.28
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-2400000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73200000	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.22
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
	us-gaap	Basis Of Accounting BasisOfAccounting	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>(1)</b></td> <td valign="top" align="left"><b>BASIS OF PRESENTATION</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The accompanying condensed consolidated financial statements have been prepared by Myriad Genetics, Inc. (the “Company”) in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The condensed consolidated financial statements herein should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2015, included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015. Operating results for the three and nine months ended March 31, 2016 may not necessarily be indicative of results to be expected for any other interim period or for the full year.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>New Accounting Pronouncements</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In February 2016, the FASB issued Accounting Standards Update 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective beginning in the first quarter of 2019. Early adoption of ASU 2016-02 is permitted. ASU 2016-02 requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company’s management is currently evaluating the impact of adopting ASU 2016-02 on the Company’s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation—Stock Compensation (Topic 718). (“ASU 2016-09”), ASU 2016-09 makes several modifications to Topic 718 related to the accounting for forfeitures, employer tax withholding on share-based compensation and the financial statement presentation of excess tax benefits or deficiencies. ASU 2016-09 also clarifies the statement of cash flows presentation for certain components of share-based awards. ASU 2016-09 is effective for interim and annual reporting periods beginning after December 15, 2016, although early adoption is permitted. The Company’s management is currently evaluating how the adoption of ASU 2016-09 will impact the Company’s Consolidated Financial Statements.</p> </div>
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	17900000
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1000000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	88300000
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	532000000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	8700000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-4100000
	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	15300000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	28500000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	20000000
	us-gaap	Depreciation Depreciation	10600000
	us-gaap	Operating Income Loss OperatingIncomeLoss	131200000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	200000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	131700000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	400000
	us-gaap	Revenues Revenues	567400000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	28700000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	500000
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-31500000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	500000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2800000
	us-gaap	Net Income Loss NetIncomeLoss	89600000
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	35400000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	200000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	131400000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1500000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	107900000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9400000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-1800000
	us-gaap	Cost Of Revenue CostOfRevenue	98600000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42100000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	85900000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	23500000
	us-gaap	Costs And Expenses CostsAndExpenses	436200000
	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	600000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	56400000
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	4100000
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	200000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6900000
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	17900000
	us-gaap	Share Based Compensation ShareBasedCompensation	23900000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	267800000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2900000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	86600000
	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	100000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-47600000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51100000
	mygn	Percent Of Employee Contribution To Deferred Savings Plan PercentOfEmployeeContributionToDeferredSavingsPlan	0.50	pure
	mygn	Cost Of Pharmaceutical And Clinical Services CostOfPharmaceuticalAndClinicalServices	18700000
	mygn	Employers Contribution Not To Exceed Percentage Of Employees Compensation EmployersContributionNotToExceedPercentageOfEmployeesCompensation	0.04	pure
	mygn	Amount Charged To Retained Earnings As Result Of Stock Repurchases AmountChargedToRetainedEarningsAsResultOfStockRepurchases	81900000
	mygn	Amount Of Reduction In Common Stock As Result Of Stock Repurchases AmountOfReductionInCommonStockAsResultOfStockRepurchases	26000000
CY2015Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3200000	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70700000	shares
CY2015Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.40	pure
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73900000	shares
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	18100000
CY2015Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	173000000
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-300000
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	35700000
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	35500000
CY2015Q1	us-gaap	Revenues Revenues	180000000
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	100000
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-200000
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	21400000
CY2015Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	7000000
CY2015Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3300000
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.46
CY2015Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6400000
CY2015Q1	us-gaap	Depreciation Depreciation	3300000
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3100000
CY2015Q1	us-gaap	Cost Of Revenue CostOfRevenue	33000000
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14100000
CY2015Q1	us-gaap	Costs And Expenses CostsAndExpenses	144300000
CY2015Q1	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1300000
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	12500000
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	91300000
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16700000
CY2015Q1	mygn	Amount Charged To Retained Earnings As Result Of Stock Repurchases AmountChargedToRetainedEarningsAsResultOfStockRepurchases	46800000
CY2015Q1	mygn	Amount Of Reduction In Common Stock As Result Of Stock Repurchases AmountOfReductionInCommonStockAsResultOfStockRepurchases	15200000
CY2015Q1	mygn	Cost Of Pharmaceutical And Clinical Services CostOfPharmaceuticalAndClinicalServices	3300000
CY2016Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2600000	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70900000	shares
CY2016Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.24	pure
CY2016Q1	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	600000
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73500000	shares
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.44
CY2016Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	33400000
CY2016Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	177400000
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	200000
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	42600000
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	43100000
CY2016Q1	us-gaap	Revenues Revenues	190500000
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	300000
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	500000
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	32600000
CY2016Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	13100000
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	300000
CY2016Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	500000
CY2016Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6600000
CY2016Q1	us-gaap	Depreciation Depreciation	3500000
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3100000
CY2016Q1	us-gaap	Cost Of Revenue CostOfRevenue	33600000
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10500000
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	147900000
CY2016Q1	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1400000
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7600000
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	90500000
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17200000
CY2016Q1	mygn	Amount Charged To Retained Earnings As Result Of Stock Repurchases AmountChargedToRetainedEarningsAsResultOfStockRepurchases	33300000
CY2016Q1	mygn	Amount Of Reduction In Common Stock As Result Of Stock Repurchases AmountOfReductionInCommonStockAsResultOfStockRepurchases	11200000
CY2016Q1	mygn	Cost Of Pharmaceutical And Clinical Services CostOfPharmaceuticalAndClinicalServices	6600000
CY2016Q1	mygn	Increase Decrease In Long Term Liabilities IncreaseDecreaseInLongTermLiabilities	600000

Files In Submission

Name	View Source	Status
0001193125-16-576683-index-headers.html	Edgar Link	pending
0001193125-16-576683-index.html	Edgar Link	pending
0001193125-16-576683.txt	Edgar Link	pending
0001193125-16-576683-xbrl.zip	Edgar Link	pending
d173578d10q.htm	Edgar Link	pending
d173578dex101.htm	Edgar Link	pending
d173578dex102.htm	Edgar Link	pending
d173578dex103.htm	Edgar Link	pending
d173578dex104.htm	Edgar Link	pending
d173578dex311.htm	Edgar Link	pending
d173578dex312.htm	Edgar Link	pending
d173578dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mygn-20160331.xml	Edgar Link	completed
mygn-20160331.xsd	Edgar Link	pending
mygn-20160331_cal.xml	Edgar Link	unprocessable
mygn-20160331_def.xml	Edgar Link	unprocessable
mygn-20160331_lab.xml	Edgar Link	unprocessable
mygn-20160331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MYGN
MYRIAD GENETICS INC Stock $mygn

2016 Q2 Form 10-Q Financial Statement

#000119312516576683 Filed on May 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MYGN MYRIAD GENETICS INC Stock $mygn

2016 Q2 Form 10-Q Financial Statement

#000119312516576683 Filed on May 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MYGN
MYRIAD GENETICS INC Stock $mygn